Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.

Researchers at Massachusetts Institute of Technology (MIT) have developed a way to 'supercharge' vaccines to the extent that just a single dose can provide strong protection from HIV.

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or ...

The drug, in June, received FDA approval as the first twice-yearly pre-exposure prophylaxis (PrEP) option to reduce the risk ...

In two studies, scientists at Gilead, which developed lenacapavir, showed that the drug was 100% effective at protecting cisgender women from becoming HIV positive as compared to daily oral pills ...

The world’s only twice-a-year shot to prevent HIV could stop transmission — if people can get it It’s the first step in an anticipated global rollout that could protect millions.

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...